Literature DB >> 3110215

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

S J Cryz, E Fürer, A S Cross, A Wegmann, R Germanier, J C Sadoff.   

Abstract

Lipid A-free polysaccharide (PS) isolated from Pseudomonas aeruginosa immunotype 5 lipopolysaccharide (LPS) was covalently coupled to toxin A via reductive amination. The PS-toxin A conjugate was comprised of 29.8% PS and 70.2% toxin A, possessed a molecular weight of greater than 1 X 10(6), was nontoxic for animals and was nonpyrogenic for rabbits at a dose of 50 micrograms/kg body wt when administered intravenously. The conjugate evoked only mild, transient reactions upon subcutaneous administration to human volunteers. Vaccination engendered immunoglobulin G (IgG) antibody, which neutralized the cytotoxic effect of toxin A and promoted the uptake and killing of P. aeruginosa in the presence of human polymorphonuclear leukocytes. Passively transferred IgG isolated from the serum of immunized donors was far more effective at preventing fatal P. aeruginosa burn wound sepsis than paired preimmunization serum. These studies establish the potential usefulness of such a PS-toxin A conjugate as a vaccine against P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110215      PMCID: PMC442200          DOI: 10.1172/JCI113062

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A.

Authors:  B H Iglewski; J C Sadoff
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine.

Authors:  R J Jones
Journal:  J Hyg (Lond)       Date:  1979-06

3.  Peroxidase-labeled antibody. A new method of conjugation.

Authors:  P K Nakane; A Kawaoi
Journal:  J Histochem Cytochem       Date:  1974-12       Impact factor: 2.479

4.  Immunization against Pseudomonas in infection after thermal injury.

Authors:  J Wesley; A Fisher; M W Fisher
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

5.  Prevention of pseudomonas respiratory infection in a surgical intensive care unit.

Authors:  H C Polk; S Borden; J A Aldrete
Journal:  Ann Surg       Date:  1973-05       Impact factor: 12.969

6.  Pseudomonas aeruginosa vaccine in cancer patients.

Authors:  L S Young; R D Meyer; D Armstrong
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

7.  Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis.

Authors:  J E Pennington; H Y Reynolds; R E Wood; R A Robinson; A S Levine
Journal:  Am J Med       Date:  1975-05       Impact factor: 4.965

8.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

9.  Analytical characterization of lipopolysaccharide antigens from seven strains of Pseudomonas aeruginosa.

Authors:  D Horton; G Rodemeyer; T H Haskell
Journal:  Carbohydr Res       Date:  1977-05       Impact factor: 2.104

10.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

View more
  27 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Authors:  A W Zuercher; M A Imboden; S Jampen; D Bosse; M Ulrich; H Chtioui; B H Lauterburg; A B Lang
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.

Authors:  J U Que; S J Cryz; R Ballou; E Fürer; M Gross; J Young; G F Wasserman; L A Loomis; J C Sadoff
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

Review 4.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

5.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

6.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

7.  Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli.

Authors:  M Duchêne; C Barron; A Schweizer; B U von Specht; H Domdey
Journal:  J Bacteriol       Date:  1989-08       Impact factor: 3.490

8.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

Authors:  C Y Chu; B K Liu; D Watson; S S Szu; D Bryla; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.